EcoDrugPlus

Ptk6 Protein Tyrosine Kinase 6b

Ensembl ID : ENSLCAG00010026612
Gene Symbol: LOC108887432
4 Cross references
159 Possible Orthologues:

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSLCAG00010010663
Gene Symbol: LOC108882691
4 Cross references
243 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase A

Ensembl ID : ENSLCAG00010019431
Gene Symbol: RAF1A
4 Cross references
207 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSLCAG00010021503
Gene Symbol: ROCK2
2 Cross references
222 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSLCAG00010003318
Gene Symbol: LOC108883337
4 Cross references
213 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSLCAG00010018281
Gene Symbol: SEM1
4 Cross references
155 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSLCAG00010015313
Gene Symbol: SRC
2 Cross references
192 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSLCAG00010006995
Gene Symbol: LOC108874619
4 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSLCAG00010002734
Gene Symbol: LOC108894916
4 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSLCAG00010005405
Gene Symbol: YES1
2 Cross references
208 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSLCAG00010020251
Gene Symbol: YES1
4 Cross references
206 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSLCAG00010016164
Gene Symbol: ACHE
1 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).